Best Management of Muscle Relaxation- Objective Monitoring
Status:
Recruiting
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that the investigators can reduce residual
paralysis to a very low incidence, and that the investigators can do this while preserving a
role for the older and less expensive reversal agent neostigmine. The investigators consider
this an evidence-based approach because previous reports clearly indicate that neostigmine is
effective for reversal of the most shallow neuromuscular blocks, a level of block now
referred to as minimal block. The Investigators also know from previous data that a
substantial proportion of patients have minimal block. Sugammadex will be used when the block
to be reversed is deeper than minimal, specifically when the objectively measured TOF-ratio
is <40%.
The investigators hypothesize that this protocol will be associated with an incidence of
residual paralysis of less than 3%. The investigators plan is to study 200 patients.